Detalles de la búsqueda
1.
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
Rheumatology (Oxford)
; 63(3): 751-764, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314967
2.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Br J Haematol
; 202(1): 40-47, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36971061
3.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Rheumatology (Oxford)
; 61(12): 4741-4751, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323903
4.
The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.
Rheumatol Int
; 42(5): 803-814, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338383
5.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Ann Rheum Dis
; 80(11): 1410-1418, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083206
6.
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Allergy
; 75(8): 1927-1938, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32108361
7.
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Hematol Oncol
; 38(4): 509-516, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32400885
8.
Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.
Rheumatol Int
; 39(3): 469-478, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30392117
9.
Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.
Clin Exp Rheumatol
; 37(2): 342-343, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30620295
10.
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
Arthritis Rheumatol
; 76(4): 587-598, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37975166
11.
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
J Rheumatol
; 50(8): 1009-1019, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455943
12.
Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA.
Ther Adv Musculoskelet Dis
; 14: 1759720X221081649, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35321118
13.
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
Arthritis Care Res (Hoboken)
; 74(7): 1205-1218, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33460531
14.
Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry.
Arthritis Res Ther
; 23(1): 11, 2021 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33407803
15.
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
Expert Opin Biol Ther
; 20(2): 183-192, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31736377
Resultados
1 -
15
de 15
1
Próxima >
>>